<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000
COMMISSION FILE NUMBER 0-12042
BIOGEN, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
MASSACHUSETTS 04-3002117
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
</TABLE>
14 CAMBRIDGE CENTER, CAMBRIDGE, MA 02142
(617) 679-2000
(Address, including zip code, and telephone
number, including area code, of registrant's
principal executive offices)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [ X ] No [ ]
The number of shares of the registrant's Common Stock, $0.01 par value,
outstanding as of April 30, 2000 was 148,477,445 shares.
1
<PAGE> 2
BIOGEN, INC.
INDEX
<TABLE>
<CAPTION>
PART I - FINANCIAL INFORMATION PAGE NUMBER
<S> <C>
Condensed Consolidated Statements of Income - Three months ended March 31, 2000 and 1999 3
Condensed Consolidated Balance Sheets - March 31, 2000 and December 31, 1999 4
Condensed Consolidated Statements of Cash Flows -
Three months ended March 31, 2000 and 1999 5
Notes to Condensed Consolidated Financial Statements 6
Management's Discussion and Analysis of Financial Condition and Results of Operations 10
PART II - OTHER INFORMATION 15
</TABLE>
Note concerning trademarks: AVONEX(R) is a registered trademark of Biogen, Inc.
2
<PAGE> 3
BIOGEN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands, except per share amounts)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
2000 1999
<S> <C> <C>
REVENUES:
Product $174,596 $131,320
Royalties 42,252 40,400
-------- --------
Total revenues 216,848 171,720
-------- --------
COSTS AND EXPENSES:
Cost of revenues 28,623 24,870
Research and development 63,006 50,987
Selling, general and administrative 41,183 33,861
-------- --------
Total costs and expenses 132,812 109,718
-------- --------
Income from operations 84,036 62,002
Other income, net 99,024 6,184
-------- --------
INCOME BEFORE INCOME TAXES 183,060 68,186
Income taxes 61,694 22,502
-------- --------
NET INCOME $121,366 $ 45,684
======== ========
BASIC EARNINGS PER SHARE $ 0.81 $ 0.31
======== ========
DILUTED EARNINGS PER SHARE $ 0.77 $ 0.29
======== ========
SHARES USED IN COMPUTING:
Basic earnings per share 150,360 149,397
======== ========
Diluted earnings per share 157,712 157,530
======== ========
</TABLE>
See Notes to Condensed Consolidated Financial Statements.
3
<PAGE> 4
BIOGEN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
<TABLE>
<CAPTION>
March 31, December 31,
2000 1999
----------- -----------
(unaudited)
<S> <C> <C>
ASSETS
Current assets
Cash and cash equivalents $ 102,039 $ 56,920
Marketable securities 566,791 597,619
Accounts receivable, net 135,494 137,363
Deferred tax assets 58,075 50,565
Other current assets 92,253 67,759
----------- -----------
Total current assets 954,652 910,226
----------- -----------
Property, plant and equipment
Cost 381,699 351,566
Less accumulated depreciation 117,881 111,789
----------- -----------
Property, plant and equipment, net 263,818 239,777
----------- -----------
Patents, net 13,883 13,871
Marketable securities 44,228 98,017
Other assets 13,019 16,082
----------- -----------
$ 1,289,600 $ 1,277,973
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable $ 24,227 $ 30,125
Current portion of long-term debt 4,888 4,888
Accrued expenses and other 133,566 155,257
----------- -----------
Total current liabilities 162,681 190,270
----------- -----------
Long-term debt, less current portion 51,268 52,073
Other long-term liabilities 57,873 56,100
Commitments and contingencies -- --
Shareholders' equity
Common stock 1,512 1,507
Additional paid-in capital 744,833 676,673
Retained earnings 382,328 352,016
Accumulated other comprehensive income 24,519 45,618
Treasury stock, at cost (135,414) (96,284)
----------- -----------
Total shareholders' equity 1,017,778 979,530
----------- -----------
$ 1,289,600 $ 1,277,973
=========== ===========
</TABLE>
See Notes to Condensed Consolidated Financial Statements.
4
<PAGE> 5
BIOGEN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
2000 1999
--------- ---------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net income $ 121,366 $ 45,684
Adjustments to reconcile net income to
net cash provided from operating activities:
Depreciation and amortization 8,233 6,620
Deferred income taxes 273 (1,491)
Other (780) (349)
Gain on sale of non-current marketable securities (92,447) --
Changes in:
Accounts receivable 1,869 (857)
Other current and other assets 4,705 2,883
Accounts payable, accrued expense and
other current and long-term liabilities (25,491) (22,677)
--------- ---------
Net cash from operating activities 17,728 29,813
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of marketable securities (196,483) (139,465)
Proceeds from sales and maturities of marketable securities 229,990 110,668
Proceeds from sales of non-current marketable securities 91,958 --
Acquisitions of property and equipment (34,653) (12,618)
Additions to patents (1,249) (1,092)
--------- ---------
Net cash from investing activities 89,563 (42,507)
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of long-term debt (805) (805)
Purchases of treasury stock (149,470) --
Proceeds from put warrants -- 8,332
Issuance of common stock, stock option exercises and related
tax benefits 88,103 71,161
--------- ---------
Net cash from investing activities (62,172) 78,688
--------- ---------
NET INCREASE IN CASH AND CASH EQUIVALENTS 45,119 65,994
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 56,920 25,445
--------- ---------
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 102,039 $ 91,439
========= =========
</TABLE>
See Notes to Condensed Consolidated Financial Statements.
5
<PAGE> 6
BIOGEN, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. BASIS OF PRESENTATION
In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments, consisting of only normal
recurring accruals, necessary to present fairly the financial position, results
of operations and cash flows of Biogen, Inc. and its subsidiaries (the
"Company"). The Company's accounting policies are described in the Notes to the
Consolidated Financial Statements in the Company's 1999 Annual Report on Form
10-K. Interim results are not necessarily indicative of the operating results
for the full year.
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements, and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates. Certain amounts for the three
months ended March 31, 1999 have been reclassified to conform to the current
period presentation.
INVENTORIES
Inventories are stated at the lower of cost or market with cost determined under
the first-in/first-out ("FIFO") method and are included in other current assets.
Included in inventory are raw materials used in the production of pre-clinical
and clinical products which are expensed as research and development costs when
consumed. The components of inventories are as follows:
<TABLE>
<CAPTION>
March 31, December 31,
(in thousands) 2000 1999
------- -------
<S> <C> <C>
Raw materials $ 6,467 $ 5,679
Work in process 15,423 15,110
Finished goods 19,013 19,242
------- -------
$40,903 $40,031
======= =======
</TABLE>
2. FINANCIAL INSTRUMENTS
On June 15, 1998, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 133, "Accounting for Derivative Instruments
and Hedging Activities", ("SFAS 133"). The Company elected to adopt SFAS 133 in
the fourth quarter of 1998. All derivatives are recognized on the balance sheet
at their fair value. Changes in the fair value of derivatives are recorded each
period in current earnings or other comprehensive income, depending on whether a
derivative is designated as part of a hedge transaction and, if it is, the type
of hedge transaction. The Company assesses, both at its inception and on an
on-going basis, whether the derivatives that are used in hedging transactions
are highly effective in offsetting the changes in cash flows of hedged items.
The Company assesses hedge ineffectiveness on a quarterly basis and records the
gain or loss related to the ineffective portion to current earnings to the
extent significant. If the Company determines that a hedged forecasted
transaction is no longer probable of occurring, the Company discontinues hedge
accounting for the affected portion of the transaction, and any unrealized gain
or loss on the contract is recognized in current earnings.
As of March 31, 2000, the Company had $17.5 million outstanding under a floating
rate loan secured by the Company's laboratory and office building in Cambridge,
Massachusetts and $38.7 million outstanding under a floating rate loan agreement
for financing the construction of its biological manufacturing facility in North
Carolina. The Company uses interest rate swap agreements to mitigate the risk
associated with its floating rate debt. The fair value of the interest rate swap
agreements at March 31, 2000, representing the cash the Company would receive to
settle the agreements, was approximately $691,000. The fair value of
6
<PAGE> 7
the interest rate swap agreements at March 31, 1999, representing the cash
requirements of the Company to settle the agreements, approximated $2.9 million.
The Company has designated the interest rate swaps as cash flow hedges. There
were no amounts of hedge ineffectiveness related to the Company's interest rate
swaps during the three months ended March 31, 2000 or in the comparable period
of 1999, and no gains or losses were excluded from the assessment of hedge
effectiveness. The Company records the differential to be paid or received on
the interest rate swaps as incremental interest expense.
The Company has foreign currency forward contracts to hedge specific forecasted
transactions denominated in foreign currencies. All foreign currency forward
contracts have durations of ninety days to 18 months. These contracts have been
designated as cash flow hedges and accordingly, to the extent effective, any
unrealized gains or losses on these foreign currency forward contracts are
reported in other comprehensive income. Realized gains and losses for the
effective portion are recognized with the underlying hedge transaction. The
notional settlement amount of the foreign currency forward contracts outstanding
at March 31, 2000 was approximately $151.5 million. These contracts had a fair
value of approximately $12 million, representing an unrealized gain, and was
included in other current assets at March 31, 2000.
For the three months ended March 31, 2000 and 1999, there were no significant
amounts recognized in earnings due to hedge ineffectiveness or as a result of
the discontinuance of cash flow hedge accounting because it was no longer
probable that the hedge forecasted transaction would occur. The Company
recognized $2.4 million of gains in product revenue and $600,000 of gains in
royalty revenue for the settlement of certain effective cash flow hedge
instruments during the period ended March 31, 2000. For the three months ended
March 31, 1999, the Company recognized a $950,000 gain in product revenue and a
$535,000 gain in royalty revenue for the settlement of certain cash flow hedge
instruments during the period. These settlements were recorded in the same
period as the related forecasted transactions affecting earnings.
3. COMPREHENSIVE INCOME
Comprehensive income is comprised of net income and other comprehensive income.
Other comprehensive income includes certain changes in equity that are excluded
from net income, such as translation adjustments and unrealized holding gains
and losses on available-for-sale marketable securities, net of tax and certain
derivative instruments, net of tax. Comprehensive income for the three months
ended March 31, 2000 and 1999 was $100.3 million and $49 million, respectively.
4. EARNINGS PER SHARE
The Company calculates earnings per share in accordance with Statement of
Financial Accounting Standards No. 128, "Earnings per Share". Basic earnings per
share is computed by dividing the net income available to common shareholders by
the weighted average number of shares of common stock outstanding. For purposes
of calculating diluted earnings per share the denominator includes both the
weighted average number of shares of common stock outstanding and the number of
dilutive common stock equivalents such as stock options and warrants. Options to
purchase approximately 1,900 shares were outstanding at March 31, 2000 but not
included in the computation of diluted earnings per share because the options'
exercise prices were greater than the average market price during the period.
The put warrants sold in connection with the Company's stock repurchase program
did not have an additional dilutive effect. Shares used in calculating basic and
diluted earnings per share for the three-month periods ending March 31, are as
follows:
<TABLE>
<CAPTION>
(in thousands) 2000 1999
---- ----
<S> <C> <C>
Weighted average number of shares
of common stock outstanding 150,360 149,397
Dilutive stock options 7,352 8,133
------- -------
Shares used in calculating diluted
earnings per share 157,712 157,530
======= =======
</TABLE>
7
<PAGE> 8
On June 11, 1999, the Board of Directors declared a two-for-one stock split to
be effected in the form of a stock dividend of one share of common stock for
each share outstanding. The stock dividend was payable on June 25, 1999 to
shareholders of record at the close of business on June 11, 1999. All references
to number of shares and per share amounts in the financial statements have been
restated to give effect to the stock split for all periods presented.
5. SHARE REPURCHASE PROGRAM
On February 22, 1999, the Company announced that its Board of Directors had
authorized the repurchase of up to 8 million shares of the Company's common
stock. The repurchased stock will provide the Company with treasury shares for
general corporate purposes, such as stock to be issued under employee stock
option and stock purchase plans. Stock purchases are expected to occur from time
to time through 2000. The stock repurchase program may be discontinued at any
time. During the first quarter of 2000, the Company repurchased approximately
1.8 million shares of its common stock at a cost of $149.5 million.
To enhance the 1999 stock repurchase program, the Company sold put warrants to
and purchased call options from independent third parties for a total of 4
million shares, of which 1.6 million were outstanding at March 31, 2000 at a
strike price of $49.47. Additionally, during 1999 in a separate put warrant
program to facilitate its purchase of common stock, the Company sold put
warrants for total proceeds of $22.1 million. The Company had put warrants to
purchase 400,000 shares outstanding at March 31, 2000 at an average strike price
of $59.22 relating to this put warrant program. All of the Company's put
warrants outstanding are exercisable only at the date of expiration, with
expiration dates ranging from April through November of 2000. The outstanding
put warrants permit a net-share settlement at the Company's option and,
therefore, did not result in a put obligation on the Company's Consolidated
Balance Sheets.
6. OTHER INCOME, NET
Other income, net consists of the following (in thousands):
<TABLE>
<CAPTION>
March 31,
--------
2000 1999
-------- --------
<S> <C> <C>
Interest income $ 10,737 $ 7,797
Interest expense (1,108) (1,186)
Other income (expense) 89,395 (427)
-------- --------
Total other income, net $ 99,024 $ 6,184
======== ========
</TABLE>
Other income for the three-months ended March 31, 2000 includes non-recurring
gains on the sale of certain non-current marketable securities totaling
approximately $92.4 million.
7. INCOME TAX EXPENSE
Income tax expense as a percentage of pre-tax income for the quarters ended
March 31, 2000 and 1999 was 33.7% and 33%, respectively. During the quarter
ended March 31, 2000, the Company recognized non-recurring gains on the sale of
certain non-current marketable securities. Excluding the tax effect on this
non-recurring gain, the Company's effective tax rate for the quarter was 30%.
The effective tax rate varied from the U.S. statutory rates for the first
quarter of 2000 and 1999 primarily due to increased European sales and to the
utilization of research and development credits. The Company's effective tax
rate outside the U.S. is lower than the U.S. tax rate, and the Company expects
that the U.S. tax rate will decline as a percentage of its total tax rate as
international sales increase.
8
<PAGE> 9
8. LITIGATION
On July 3, 1996, Berlex Laboratories, Inc. ("Berlex") filed suit against Biogen
in the United States District Court for the District of New Jersey alleging
infringement by Biogen of Berlex's "McCormick" patent (U.S. Patent No.
5,376,567) in the United States in the production of Biogen's AVONEX(R)
(Interferon beta-1a) product. In November 1996, Berlex's New Jersey action was
transferred to the United States District Court in Massachusetts and
consolidated for pre-trial purposes with a related declaratory judgment action
previously filed by Biogen. On August 18, 1998, Berlex filed a second suit
against Biogen alleging infringement by Biogen of a patent which was issued to
Berlex in August 1998 and which is related to the McCormick patent (U.S. Patent
No. 5,795,779). On September 23, 1998, the cases were consolidated for pre-trial
and trial purposes. Berlex seeks a judgment granting it damages, a trebling of
any damages awarded and a permanent injunction restraining Biogen from the
alleged infringement. An unfavorable ruling in the Berlex suit could have a
material adverse effect on the Company's results of operations and financial
position. The Company believes that it has meritorious defenses to the Berlex
claims, but the ultimate outcome is not currently determinable. As a result, an
estimate of any potential loss or range of loss cannot be made at this time. A
hearing on the parties' summary judgment motions was completed in March 2000.
Biogen moved for summary judgment of non-infringement of certain claims of the
'567 patent, non-infringement of the '779 patent, as well as a determination of
the invalidity of certain claims of the '567 patent and all of the claims of the
'779 patent. Berlex moved to dismiss Biogen's inequitable conduct defenses and
counterclaims. Berlex also moved for a declaration of literal infringement of
certain claims of the '567 and the '779 patents. No decisions have been rendered
to date. The Company expects a trial to occur in the second half of 2000.
In 1995, the Company filed an opposition with the Opposition Division of the
European Patent Office to oppose a European patent (the "Rentschler I Patent")
issued to Dr. Rentschler Biotechnologie GmbH ("Rentschler") relating to
compositions of matter of beta interferon. In 1997, the European Patent Office
issued a decision to revoke the Rentschler I Patent. Rentschler has appealed
that decision and the appeal is still pending. A hearing on the appeal has been
scheduled for December 2000. On October 13, 1998, the Company filed another
opposition with the Opposition Division of the European Patent Office to oppose
a second European patent issued to Rentschler (the "Rentschler II Patent") with
certain claims regarding compositions of matter of beta interferon with specific
regard to the structure of the glycosylated molecule. A hearing on the Company's
opposition has been scheduled for October 2000. While Biogen believes that the
Rentschler II Patent will be revoked and that the revocation of the Rentschler I
Patent will be upheld on appeal, if either the Rentschler I Patent or the
Rentschler II Patent were to be upheld and if Rentschler were to obtain, through
legal proceedings, a determination that the Company's sale of AVONEX(R) in
Europe infringes a valid Rentschler patent, such result could have a material
adverse effect on the Company's results of operation and financial position.
9. SEGMENT INFORMATION
The chief operating decision makers review the profit and loss of the Company on
an aggregate basis and manage the operations of the Company as a single
operating segment. Accordingly, the Company operates in one segment, which is
the business of developing, manufacturing and marketing drugs for human health
care. The Company currently derives product revenues from sales of its AVONEX(R)
(Interferon beta-1a) product for the treatment of relapsing forms of multiple
sclerosis. The Company also derives revenue from royalties on worldwide sales by
the Company's licensees of a number of products covered under patents controlled
by the Company, including alpha interferon and hepatitis B vaccines and
diagnostic products.
9
<PAGE> 10
BIOGEN, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
OVERVIEW
Biogen, Inc. (the "Company" or "Biogen") is a biopharmaceutical company
principally engaged in the business of developing, manufacturing and marketing
drugs for human health care. The Company currently derives revenues from sales
of its AVONEX(R) (Interferon beta-1a) product for the treatment of relapsing
forms of multiple sclerosis ("MS"). The Company also derives revenue from
royalties on worldwide sales by the Company's licensees of a number of products
covered under patents controlled by the Company, including alpha interferon and
hepatitis B vaccines and diagnostic products.
RESULTS OF OPERATIONS
For the quarter ended March 31, 2000, the Company reported net income of $121.4
million or $0.77 per diluted share as compared to $45.7 million or $0.29 per
diluted share for the comparable period of 1999.
Total revenues for the quarter ended March 31, 2000 were $216.8 million, as
compared to $171.7 million in the same period of 1999, an increase of $45.1
million or approximately 26%.
Product revenues in the current quarter were $174.6 million as compared to
$131.3 million for the same period of 1999, an increase of $43.3 million or
approximately 33%. Product revenues from AVONEX(R) represent approximately 81%
of the Company's total revenues in the current quarter as compared to 76% for
the same period of 1999. The growth in the first quarter of 2000 over the
comparable period in 1999 was primarily attributable to an increase in the sales
volume of AVONEX(R) in the United States and in the fifteen member countries of
the European Union ("EU"). AVONEX(R) sales outside of the United States were
approximately $48.4 million in the first quarter of 2000 as compared to $36
million in 1999.
Revenues from royalties in the period ended March 31, 2000 were $42.2 million,
an increase of $1.8 million or approximately 5% as compared to $40.4 million of
royalty revenue for the same period in 1999. Revenues from royalties represented
approximately 19% of total revenues for the first three months of 2000 as
compared to 24% for the same period of 1999. The increase in royalty revenues is
primarily the result of royalties received on increased sales of alpha
interferon.
The Company expects product sales as a percentage of total revenues to continue
to increase in the near term as the Company continues to market AVONEX(R)
worldwide. The Company, however, expects to face increasing competition in the
MS marketplace from existing and new MS treatments that may impact sales of
AVONEX(R). The Company expects to experience declining royalty revenues as a
result of patent expirations. In 2000, the Company expects the decline in
royalty revenues to be partially offset by increasing overall sales of licensed
products. In addition, sales levels of products sold by the Company's licensees
may also fluctuate from quarter to quarter due to the timing and extent of major
events such as new indication approvals or government sponsored programs.
COSTS AND EXPENSES
Total costs and expenses for the current quarter of 2000 were $132.8 million as
compared to $109.7 million in the same period of 1999, an increase of
approximately 21%.
Cost of revenues in the first three months of 2000 totaled $28.6 million, an
increase of $3.7 million or 15% as compared to the comparable period in 1999.
The increase in cost of revenues was attributable to the higher sales volume of
AVONEX(R). Included in cost of revenues for the period ended March 31, 2000 and
1999 is $26 million and $21.4 million, respectively, of costs related to product
revenues and $2.6 million and $3.5 million, respectively, of costs related to
royalty revenue. Gross margins on product revenues increased to approximately
85% for the period ended March 31, 2000 compared to 84% in the same period in
1999.
10
<PAGE> 11
Gross margins on royalty revenue increased to approximately 94% for the period
ended March 31, 2000 compared to 91% in the same period in 1999. The Company
expects that gross margins on royalty revenue will fluctuate in the future based
on changes in sales volumes for specific products.
Research and development expenses in the current quarter were $63 million, an
increase of $12 million or 24% as compared to $51 million in the same period of
1999. The increase was primarily due to an increase in clinical trial costs and
the costs associated with an increase in the Company's other development efforts
related to its ongoing research and development programs. The Company expects
that, in the near and long-term, research and development expenses will increase
as the Company continues to expand its development efforts with respect to new
products, conducts clinical trials of these products and continues work on new
formulations and delivery methods for AVONEX(R).
Selling, general and administrative expenses in the first quarter of 2000 were
$41.2 million, an increase of $7.3 million or 22% as compared to the same period
of 1999. This increase was primarily due to an increase in selling and marketing
expenses related to the sale of AVONEX(R). The Company expects that selling,
general and administrative expenses will continue to increase in the near term
as the Company continues to expand its sales and marketing organizations
necessary to sell AVONEX(R) worldwide.
OTHER INCOME, NET
Other income, net consists primarily of interest income, partially offset by
interest expenses and other non-operating income and expenses. Other income, net
in the current quarter of 2000 was $99 million as compared to $6.2 million in
1999, an increase of $92.8 million. Interest income for the first quarter of
2000 was $10.7 million compared to $7.8 million in the same period of 1999, an
increase of $2.9 million or 37% due primarily to an increase in funds invested.
In the first quarter of 2000 interest expense decreased to $1.1 million from
$1.2 million compared to the same period in 1999. Other income (expense)
increased by $89.8 million in the first three months of 2000 from the same
period in 1999, due primarily to the sale of certain non-current marketable
securities generating non-recurring gains of approximately $92.4 million. The
Company expects interest income to vary based on changes in the amount of funds
invested and fluctuations in interest rates.
INCOME TAXES
Income tax expense as a percentage of pre-tax income for the quarters ended
March 31, 2000 and 1999 was 33.7% and 33%, respectively. During the quarter
ended March 31, 2000, the Company recognized non-recurring gains on the sale of
certain non-current marketable securities. Excluding the tax effect on this
non-recurring gain, the Company's effective tax rate for the quarter was 30%.
The effective tax rate varied from the U.S. statutory rates for the first
quarter of 2000 and 1999 primarily due to increased European sales and to the
utilization of research and development credits. The Company's effective tax
rate outside the U.S. is lower than the U.S. tax rate, and the Company expects
that the U.S. tax rate will decline as a percentage of its total tax rate as
international sales increase.
FINANCIAL CONDITION
At March 31, 2000, cash, cash equivalents and short-term marketable securities
were $668.8 million compared with $654.5 million at December 31, 1999, an
increase of $14.3 million. Working capital increased $72 million to $792
million. Net cash from operating activities for the period ended March 31, 2000
was $17.7 million compared with $29.8 million for the same period in 1999.
Significant cash inflows from investing activities during the first quarter of
2000 included $92 million in proceeds from the sale of certain non-current
marketable securities. Cash outflows during the first quarter of 2000 included
investments in property and equipment and patents of $35.9 million. Significant
cash outflows from financing activities included $149.5 million for purchases of
the Company's common stock under its stock repurchase program and $805,000 for
repayments on loan agreements with banks. Cash inflows included $88.1 million
from common stock option exercises and related tax benefits and employee stock
purchase plan activity.
11
<PAGE> 12
On February 22, 1999, the Company announced that its Board of Directors had
authorized the repurchase of up to 8 million shares of the Company's common
stock. The repurchased stock will provide the Company with treasury shares for
general corporate purposes, such as stock to be issued under employee stock
option and stock purchase plans. Stock purchases are expected to occur from time
to time through 2000. The stock repurchase program may be discontinued at any
time. During the first quarter of 2000, the Company repurchased approximately
1.8 million shares of its common stock at a cost of $149.5 million.
To enhance the 1999 stock repurchase program, the Company sold put warrants to
and purchased call options from independent third parties for a total of 4
million shares, of which 1.6 million were outstanding at March 31, 2000 at a
strike price of $49.47. Additionally, during 1999 in a separate put warrant
program to facilitate its purchase of common stock, the Company sold put
warrants for total proceeds of $22.1 million. The Company had put warrants to
purchase 400,000 shares outstanding at March 31, 2000 at an average strike price
of $59.22 relating to this put warrant program. All of the Company's put
warrants outstanding are exercisable only at the date of expiration, with
expiration dates ranging from April through November of 2000. The outstanding
put warrants permit a net-share settlement at the Company's option and,
therefore, did not result in a put obligation on the Company's Consolidated
Balance Sheets. The put warrants sold in connection with the Company's stock
repurchase program did not have an additional dilutive effect on earnings per
share.
On October 4, 1999, the Company began construction of its new research and
development center in Cambridge, Massachusetts. The new 224,000 square foot
building is expected to be completed in the spring of 2001 at a total cost of
approximately $95 million, of which $75 million had been committed at March 31,
2000. Additionally, the Company is building a large scale manufacturing plant in
Research Triangle Park, North Carolina. The Company expects that construction
will be completed at the end of 2001 at a total cost of approximately $175
million, of which $84 million had been committed at March 31, 2000.
Several legal proceedings were pending during the current quarter, which involve
the Company. See Note 8 of the Notes to the Condensed Consolidated Financial
Statements. See also Item 1 - Business, "Patents and Other Proprietary Rights"
of the Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1999 for discussions of these legal proceedings.
The Company believes that existing funds and cash generated from operations are
adequate to satisfy its working capital and capital expenditure requirements in
the foreseeable future. However, the Company may raise additional capital to
take advantage of favorable conditions in the market or in connection with the
Company's development activities.
NEW ACCOUNTING PRONOUNCEMENTS
In December 1999, the United States Securities and Exchange Commission issued
Staff Accounting Bulletin 101, "Revenue Recognition in Financial Statements"
("SAB 101"). SAB 101 provides the staff's views in applying generally accepted
accounting principles to selected revenue recognition issues, as well as
examples of how the staff applies revenue recognition guidance to specific
circumstances. The Company is currently assessing the impact, if any, however,
the Company does not currently anticipate that SAB 101 will have a material
effect on the Company's financial position and results of operations.
In March 2000, the Financial Accounting Standard Board issued FASB
Interpretation No. 44, "Accounting for Certain Transactions Involving Stock
Compensation - an interpretation of APB Opinion No. 25" ("FIN 44"). FIN 44
clarifies the application of APB Opinion No. 25 and among other issues clarifies
the following: the definition of an employee for purposes of applying APB
Opinion No. 25; the criteria for determining whether a plan qualifies as a
noncompensatory plan; the accounting consequence of various modifications to the
terms of previously fixed stock options or awards; and the accounting for an
exchange of stock compensation awards in a business combination. FIN 44 is
effective July 1, 2000, but certain conclusions in FIN 44 cover specific events
that occurred after either December 15, 1998 or January 12, 2000. The Company
does not expect the application of FIN 44 to have a material impact on the
Company's financial position or results of operations.
12
<PAGE> 13
OUTLOOK
SAFE HARBOR STATEMENT UNDER PRIVATE SECURITIES LITIGATION REFORM ACT OF 1996
In addition to historical information, this quarterly report contains
forward-looking statements that involve risks and uncertainties that could cause
actual results to differ materially from those reflected in such forward-looking
statements. Reference is made in particular to forward-looking statements
regarding the anticipated level of future product sales, royalty revenues,
expenses and profits and predictions as to the anticipated outcome of pending
litigation and patent-related proceedings. These and all other forward-looking
statements are made based on the Company's current belief as to the outcome and
timing of such future events. Factors which could cause actual results to differ
from the Company's expectations and which could negatively impact the Company's
financial condition and results of operations are discussed below and elsewhere
in this Management's Discussion and Analysis of Financial Condition and Results
of Operations.
DEPENDENCE ON AVONEX(R) SALES AND ROYALTY REVENUE
The Company's ability to sustain increases in revenues and profitability in the
near term will be primarily dependent on the level of revenues and profitability
from AVONEX(R) sales. The Company's ability to sustain profitability from sales
of AVONEX(R) will depend on a number of factors, including: continued market
acceptance of AVONEX(R) worldwide; the Company's ability to maintain a high
level of patient satisfaction with AVONEX(R); the nature of regulatory and
pricing decisions related to AVONEX(R) worldwide and the extent to which
AVONEX(R) receives and maintains reimbursement coverage; successful resolution
of the lawsuit with Berlex related to the "McCormick" patents, which if decided
in Berlex's favor could have a material adverse effect on the Company's
financial position and results of operations; success in revoking the Rentschler
patent since if the patent were to be upheld and if Rentschler were to obtain,
through legal proceedings, a determination that the Company's sale of AVONEX(R)
in Europe infringes a valid Rentschler patent, such result could have a material
adverse effect on the Company's results of operation and financial condition;
the Company's ability to sustain market share of AVONEX(R) in light of the
impact of competitive products for the treatment of MS; the success of ongoing
development work related to AVONEX(R) in expanded MS indications and the
continued accessibility of third parties to vial, label, and distribute
AVONEX(R) on acceptable terms. The Company also receives royalty revenues which
contribute significantly to its overall profitability. The Company's ability to
maintain the level of its royalty revenues will depend on a number of factors.
For example, pricing reforms, health care reform initiatives, other legal and
regulatory developments and the introduction of competitive products may have an
impact on product sales by the Company's licensees. In addition, licensee sales
levels may fluctuate from quarter to quarter due to the timing and extent of
major events such as new indication approvals or government sponsored
vaccination programs. Since the Company is not involved in the development or
sale of products by licensees, the Company is unable to predict the timing or
potential impact of factors which may affect licensee sales. The Company's
royalty revenue could also be negatively affected if there is an adverse
decision in the appeal of a claim interpretation narrowing the scope of Biogen's
alpha interferon patent. The appeal is part of an action between Schering-Plough
Corporation and Amgen, Inc. but relates to Biogen's patent. In the long term,
the Company expects its royalty revenue to be affected most significantly by
patent expirations.
There can be no assurance that the Company will achieve a positive outcome with
respect to any of the factors discussed in this Section or that the timing and
extent of the Company's success with respect to any combination of these factors
will be sufficient to result in sustained increases in revenues or profitability
or the sustained profitability of the Company. For a further discussion of risks
regarding drug development, patent matters, including the Berlex lawsuit on the
"McCormick" patents and the Amgen appeal, competition in the MS market and
regulatory matters, see the Company's Annual Report on Form 10-K for the period
ended December 31, 1999 under the headings "Business - Risks Associated with
Drug Development", "Business - Patents and Other Proprietary Rights", "Business
- - Competition and Marketing - AVONEX(R) (interferon beta-la)", "Business -
Regulation", "Legal Proceedings" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations - Outlook."
13
<PAGE> 14
PRODUCTS
AVONEX(R) is currently the only product sold by the Company. The Company's
long-term viability and growth will depend on the successful development and
commercialization of other products from its research activities and
collaborations. The Company continues to expand its development efforts related
to other potential products in its pipeline. The expansion of the pipeline may
include increases in spending on internal projects, the acquisition of
third-party technologies or products or other types of investments. Product
development involves a high degree of risk. Only a small number of research and
development programs result in the commercialization of a product. Success in
preclinical and early clinical trials does not ensure that later stage or large
scale clinical trials will be successful. Many important factors affect the
Company's ability to successfully develop and commercialize drugs, including the
ability to obtain and maintain necessary patents and licenses, to demonstrate
safety and efficacy of drug candidates at each stage of the clinical trial
process, to overcome technical hurdles that may arise, to meet applicable
regulatory standards, to receive required regulatory approvals, to be capable of
producing drug candidates in commercial quantities at reasonable costs, to
compete successfully against other products and to market products successfully.
There can be no assurance that the Company will be successful in its efforts to
develop and commercialize new products.
14
<PAGE> 15
PART II - OTHER INFORMATION
Item 5 - Other Information
On May 2, 2000, the Company announced that James C. Mullen had been named
President and Chief Executive Officer, succeeding James L. Vincent, who will
continue as Chairman of the Board. The change will be effective at the
Company's annual meeting of shareholders on June 16, 2000.
Item 6 - Exhibits and Reports on Form 8-K
(a) Exhibits
No. 27 Financial Data Schedule (for EDGAR filing purposes only).
15
<PAGE> 16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BIOGEN, INC.
Dated: May 12, 2000 /s/ Michael A. Kelly
--------------------------------------------------
Corporate Controller and Acting
Chief Financial Officer
EXHIBITS
Index to Exhibit.
No. 27 Financial Data Schedule (for EDGAR filing purposes only).
16
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<EXCHANGE-RATE> 1
<CASH> 102,039
<SECURITIES> 566,791
<RECEIVABLES> 137,136
<ALLOWANCES> 1,642
<INVENTORY> 40,903
<CURRENT-ASSETS> 954,652
<PP&E> 381,699
<DEPRECIATION> 117,881
<TOTAL-ASSETS> 1,289,600
<CURRENT-LIABILITIES> 162,681
<BONDS> 51,268
0
0
<COMMON> 1,512
<OTHER-SE> 1,016,266
<TOTAL-LIABILITY-AND-EQUITY> 1,289,600
<SALES> 174,596
<TOTAL-REVENUES> 216,848
<CGS> 26,034
<TOTAL-COSTS> 132,812
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 1,108
<INCOME-PRETAX> 183,060
<INCOME-TAX> 61,694
<INCOME-CONTINUING> 121,366
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 121,366
<EPS-BASIC> 0.81
<EPS-DILUTED> 0.77
</TABLE>
